Novartis Using CST's Phosphoscan in Pilot Study
Novartis has been using Cell Signaling Technology's PhosphoScan in a pilot study to identify phosphorylation sites and prospective biomarkers of protein kinase targets, CST said this week.
Novartis researchers can now use CST's PhosphoScan — a tool that pairs immunoaffinity purification protocol and mass spectrometry technology — to develop cellular kinase phosphor-profiles that CST said may be useful in creating biomarker assays for target validation.
Prolexys to Make Proteomic Map of TB as Part of Imperial College Consortium
As part of a collaborative research project led by Imperial College, London, Prolexys Pharmaceuticals will create a comprehensive protein-protein interaction map of Mycobacterium tuberculosis, the bacterium that causes tuberculosis, using its HyNet and HySpec platforms, the company said last week in a statement.
Prolexys did not disclose detailed financial terms of the deal.
"The detailed protein interaction map will shed a light on potential mechanisms of TB latency and therefore facilitate the discovery of drugs that eliminate the latent infection," Gary Schoolnik, a consortium member and a professor of medicine at Stanford University, said in the statement.
About 2 billion people worldwide carry latent TB, according to the statement.
The consortium is supported by a $20 million grant to Imperial College from the Grand Challenges in Global Health initiative, which is itself supported by the Bill & Melinda Gates Foundation, the Wellcome Trust, and the Canadian Institutes of Health Research, Prolexys said.
Agilix Licenses Proteomics Labeling Technology to Protana
Protana has taken a license to Agilix' protein labeling technology for proteomics, New Haven, Conn.-based Agilix said recently.
Under the non-exclusive license, Protana will offer Agilix's i-Prot technology as part of its proteomic services. The companies did not disclose the terms of the agreement. According to Agilix, i-Prot allows researchers to measure many labels simultaneously (see ProteoMonitor 12/17/2004).
Protana emerged from the ailing MDS Proteomics a year ago.
Luminex Q2 Revenues Climb 16 Percent, Loss Narrows
Luminex last week reported increased revenues and a narrowing loss for the second quarter of 2005.
Revenues for the quarter totaled $10.7 million, a 16 percent increase over last year's revenues of $9.2 million during the same quarter. Of total revenues, $4.4 million came from sales of Luminex instruments, $3.9 million from consumables, $1.2 million from royalties, and $1.1 million from other sources.
Research and development costs climbed to $1.5 million, up from $1 million during the year-ago quarter.
Luminex's net loss declined to $363,000, or $.01 per share, from $1.1 million, or $.04 per share, for last year's second quarter.
As of June 30, Luminex had $19.5 million in cash and cash equivalents, and $8.9 million in short-term investments.
Bruker Q2 Organic Revenue up 8 Percent
Bruker BioSciences this week reported second-quarter revenue of $71.4 million, an 11.3 percent increase over revenue of $64.1 million in the second quarter last year. The growth included a 3.3 percent favorable currency effect.
Though the results improved year over year, the Q2 sales represent the second sequential quarter in which revenue dropped. The firm had fourth-quarter 2004 revenue of $85.8 million and first quarter 2005 revenue of $74.9 million. Bruker had cautioned earlier this year that the first quarter was traditionally the "lowest quarter of the year" in terms of sales (see ProteoMonitor's sister publication, BioCommerce Week 3/10/2005). The firm did not provide a reason why overall sales dropped 5 percent from the first quarter.
The firm's Bruker Daltonics business, which derives roughly 70 percent of its revenue from life-science mass spectrometry systems, generated sales of $37.4 million, a gain of 7.1 percent over the comparable period last year — and 3.6 percent when currency benefits are factored in. The Bruker AXS business, which makes X-ray analysis equipment, had sales of $34.1 million in the quarter, a 16.4 percent increase over last year's second-quarter revenue of $29.3 million.
Frank Laukien, president and CEO of Bruker, said during a conference call following the release of the results that the firm was "pleased to achieve these results despite some geographical weaknesses in spending in the US and Germany." He added, "Germany is a little weak across the board right now, and I think it will remain so until probably six to eight weeks after the election. That's a temporary effect that has to do more with the German market than with our product lines."
Laukien said that sales weakness in the US was primarily due to reduced academic spending. He also cited customers possibly delaying orders as they wait for launches of the new products exhibited at the American Society for Mass Spectrometry Conference in June.
Bruker reported Q2 net earnings of $300,000, or $0.0 per share, compared with a net loss of $4.4 million, or $.05 per share, in last year's Q2.
The firm's R&D spending rose to $11 million from $10.3 million year over year.
As of June 30, Bruker listed cash and short-term investments of $92 million.